Aston Gynaecologist Investigates Ozempic, Mounjaro Impact on PCOS

In a promising development for women's health, Dr Shagaf Bakour, a gynaecologist and director of medical education at Aston Medical School, has secured a £60,000 NHS research grant through Sandwell and West Birmingham NHS Trust. Her project focuses on evaluating whether weight loss drugs like Mounjaro and Ozempic could benefit women with polycystic ovary syndrome (PCOS), a condition affecting up to one in ten women.

Understanding PCOS: A Common Yet Overlooked Condition

Polycystic ovary syndrome (PCOS) disrupts normal ovarian function, leading to a range of challenges including infertility and significant weight gain. According to the NHS, women with PCOS often experience elevated levels of male hormones (androgens), resulting in symptoms such as irregular periods, excess body or facial hair, and acne. The associated weight gain exacerbates risks for type 2 diabetes and cardiovascular problems, creating a cycle that's difficult to break without targeted interventions.

PCOS impacts reproductive health profoundly, with many women struggling with ovulation issues that hinder conception. Metabolic disturbances, including insulin resistance, are hallmarks of the condition, contributing to the weight challenges that affect up to 70-80% of those diagnosed. Early diagnosis and management are crucial, yet the condition remains underrecognized, often delaying access to effective care.

Why Weight Loss Matters for PCOS Management

Even modest weight loss—around 5-10% of body weight—can restore menstrual regularity, improve insulin sensitivity, and boost fertility rates in women with PCOS. Traditional approaches like diet and exercise help some, but many face barriers due to hormonal imbalances. This is where emerging therapies like GLP-1 receptor agonists enter the conversation, offering a potential bridge to better outcomes.

The Research Project: Spotlight on Dr Shagaf Bakour

Dr Bakour, working alongside Dr Hoda Harb, a consultant obstetrician and gynaecologist at the NHS trust, will review existing evidence on GLP-1 drugs such as Mounjaro (tirzepatide) and Ozempic (semaglutide). The study will assess their effects on both metabolic and reproductive outcomes in PCOS patients. "The research could lead to earlier support, better long-term health, and more joined-up care for a condition that affects many women but is still often overlooked," Dr Bakour stated.

The project aims to provide evidence-informed treatment options and consistent care pathways. "The aim is to give women with PCOS evidence-informed, clearer treatment options and more consistent care," she added. "The project hopes to show whether these medicines can improve both general health and fertility health, while also helping local services develop clearer care pathways."

"The effects of PCOS, including infertility, were 'very emotive subjects'. We should be doing all we can within research and development to advance healthcare for women and to better help future generations with this condition."
- Prof Elizabeth Hughes, director of research and development at Sandwell and West Birmingham NHS Trust

How GLP-1 Drugs Like Ozempic and Mounjaro Work

These medications mimic glucagon-like peptide-1 (GLP-1), a hormone that regulates blood sugar and appetite. By activating GLP-1 receptors in the gut and brain, they slow gastric emptying, signal fullness to the brain, and reduce overall calorie intake. Ozempic, primarily semaglutide, is approved for type 2 diabetes and weight management, while Mounjaro combines GLP-1 with GIP (glucose-dependent insulinotropic polypeptide) actions for enhanced weight loss effects—often 15-20% body weight reduction in trials.

Potential Relevance to PCOS

PCOS patients frequently battle insulin resistance, a key driver of weight gain and hyperandrogenism. GLP-1 drugs' ability to improve insulin sensitivity and promote substantial weight loss could indirectly alleviate symptoms like irregular periods and hirsutism. While Dr Bakour's research is exploratory, preliminary data from broader GLP-1 studies suggest benefits in metabolic profiles that align with PCOS needs, such as lowered HbA1c and reduced inflammation.

Comparing Ozempic and Mounjaro for Metabolic Health

• Ozempic (semaglutide): Weekly injection, strong evidence for cardiovascular risk reduction and diabetes control. In PCOS contexts, it may aid ovulation by curbing insulin spikes.
• Mounjaro (tirzepatide): Dual agonist, showing superior weight loss in head-to-head trials (e.g., SURMOUNT studies). Its potency could offer faster relief for PCOS-related obesity.

Neither is currently FDA/EMA-approved specifically for PCOS, but off-label use is growing under medical supervision. Patients should compare these with alternatives like metformin, which targets insulin but yields less weight loss.

Safety Considerations and Side Effects

Common side effects include nausea, vomiting, and diarrhea, typically mild and transient. Rare risks like pancreatitis or thyroid tumors require monitoring. For PCOS patients, gastrointestinal tolerance is key, as symptoms can mimic IBS-like issues common in the condition. Long-term data emphasizes the need for research like Dr Bakour's to tailor use safely, especially for fertility-seeking women.

Tools like Shotlee can help track side effects, symptoms, and medication adherence, providing valuable data for doctors during PCOS management.

Practical Guidance for Patients

If you have PCOS, discuss GLP-1 options with your gynaecologist or endocrinologist. Key questions: Does my insulin resistance profile suit these drugs? What fertility goals are realistic? Combine with lifestyle changes for best results. Early intervention could prevent diabetes and heart risks, aligning with the holistic care Dr Bakour envisions.

Key Takeaways: What This Means for PCOS Patients

• Dr Shagaf Bakour's £60,000-funded study evaluates Ozempic and Mounjaro for PCOS metabolic and reproductive benefits.
• PCOS affects 1 in 10 women, linking weight gain to infertility, diabetes, and heart issues.
• GLP-1 drugs suppress appetite via hormone mimicry, potentially breaking the PCOS weight cycle.
• Expect clearer care pathways from this research, emphasizing evidence-based options.
• Consult professionals; monitor progress closely for optimal outcomes.

Conclusion: Advancing PCOS Care Through Research

Dr Bakour's investigation represents a vital step toward integrated PCOS management, potentially unlocking GLP-1 drugs' role in fertility and metabolic health. As evidence builds, women gain actionable insights for better health. Stay informed on updates from Sandwell and West Birmingham NHS Trust, and prioritize discussions with your healthcare team for personalized plans.